COMPOSITION OF PROBIOTIC AGENT BASED ON BACTERIAL CULTURES STRAINS PEDIOCOCCUS ACIDILACTICI VKM B-3708D (PEDIOCOCCUS ACIDILACTICI 385), LACTICASEIBASILLUS PARACASEI VKM B-3709D (LACTICASEIBASILLUS PARACASEI CTR079) AND WEISELLA CIBARIA VKM B-3710D (WEISELLA CIBARIA 079_18), INTENDED FOR PREVENTION AND THERAPY OF ANTIBIOTIC-ASSOCIATED INFECTION AND THERAPY OF FUNCTIONAL INTESTINAL DISEASES Russian patent published in 2024 - IPC A61K9/19 A61K35/744 A61K35/747 A61P1/00 A61P1/12 A61P31/00 

FIELD: biotechnology; pharmaceutics.

SUBSTANCE: disclosed is a composition of a pharmaceutical substance of a probiotic agent for preventing and treating antibiotic-associated diarrhoea and intestinal diseases, containing lyophilisates of living cells of probiotic strains of bacterial cultures isolated from the human intestinal biotope Pediococcus acidilactici VKM B-3708D, Lacticaseibacillus paracasei VKM B-3709D and Weissella cibaria VKM B-3710D, freeze-dried in a protective medium, in a sugar-gelatinous medium or in a medium with addition of 20% defatted milk. Obtained composition is a crystalline or porous mass of whitish-grey or yellowish-beige colour of various intensity and contains not less than 5.0 × 10⁸ CFU/cm³ of each of the listed probiotic strains. Bacterial strains contained in the composition are characterized by high antagonist activity with respect to pathogenic, opportunistic, including polyresistive to antibacterial preparations, microorganisms.

EFFECT: composition enables increasing the number of favourable clinical outcomes of the diseases, improving the patient’s quality of life and reducing the costs of alternative therapeutic options, such as anti-cytokine therapy and antibacterial therapy.

3 cl, 3 dwg, 6 tbl, 10 ex